Scientech Research LLC Increases Stake in Genmab A/S Sponsored ADR $GMAB

Key Points

• Scientech Research LLC increased its stake in Genmab A/S by 209.5% in Q1, holding 34,611 shares worth $678,000, signaling significant investor interest.
• Barclays PLC notably raised its holdings in Genmab by 1,072.8% during the last quarter, reflecting a broader trend of institutional investors accumulating shares.
• Analysts have a consensus rating of "Moderate Buy" for Genmab A/S, with an average target price of $37.60, indicating positive sentiment about the company's future performance.

Scientech Research LLC raised its stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 209.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 34,611 shares of the company's stock after purchasing an additional 23,428 shares during the quarter. Scientech Research LLC's holdings in Genmab A/S were worth $678,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. Marotta Asset Management raised its stake in shares of Genmab A/S by 5.8% during the first quarter. Marotta Asset Management now owns 13,532 shares of the company's stock worth $265,000 after acquiring an additional 739 shares in the last quarter. Gallacher Capital Management LLC raised its stake in shares of Genmab A/S by 6.8% during the first quarter. Gallacher Capital Management LLC now owns 14,346 shares of the company's stock worth $281,000 after acquiring an additional 915 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its stake in shares of Genmab A/S by 124.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock worth $38,000 after acquiring an additional 1,070 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Genmab A/S by 27.2% during the first quarter. Smartleaf Asset Management LLC now owns 5,772 shares of the company's stock worth $115,000 after acquiring an additional 1,236 shares in the last quarter. Finally, Headlands Technologies LLC raised its stake in shares of Genmab A/S by 1,525.0% during the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock worth $31,000 after acquiring an additional 1,464 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Stock Down 2.8%

GMAB stock traded down $0.79 during midday trading on Friday, hitting $27.82. The company's stock had a trading volume of 1,484,403 shares, compared to its average volume of 1,383,707. Genmab A/S Sponsored ADR has a 12 month low of $17.24 and a 12 month high of $28.75. The firm has a market capitalization of $17.85 billion, a price-to-earnings ratio of 13.98, a price-to-earnings-growth ratio of 1.62 and a beta of 0.93. The company has a 50 day moving average of $23.55 and a two-hundred day moving average of $21.64.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.15. The business had revenue of $925.00 million during the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. On average, analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on GMAB shares. Wall Street Zen raised shares of Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th. Truist Financial lifted their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. Zacks Research downgraded shares of Genmab A/S from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Finally, HC Wainwright boosted their target price on shares of Genmab A/S from $35.00 to $36.00 and gave the company a "buy" rating in a report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $39.25.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.